Cancer

The Tidal study

A Multicenter, Open-Label, Single-Arm, Phase 2 Study of Zandelisib in Subjects with Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies

Trial overview

Disease

Lymphoma

Topic

The Tidal study

Sponsor

Description

This is a global, multicenter open-label, single-arm, Phase 2 study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy which must have included an anti-CD20 antibody and chemotherapy with an alkylating agent or a purine analogueApproximately 180 subjects will be enrolled and treated with Zandelisib (ME-401) on the intermittent schedule.

Study details

For detailed information on this trial, please click here

Trial status

Actively recruiting

Location

Principle Investigator

Dr Graham Collins

MBBS, MA, MRCP, FRCPath, DPhil

Haematology Consultant

Oxford